{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:55:09Z","timestamp":1758477309213},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,7,28]],"date-time":"2007-07-28T00:00:00Z","timestamp":1185580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s10549-007-9667-8","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T13:21:17Z","timestamp":1185542477000},"page":"443-450","source":"Crossref","is-referenced-by-count":8,"title":["Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity"],"prefix":"10.1007","volume":"109","author":[{"given":"Hiromi","family":"Sakaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Tomonari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehiro","family":"Ohdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,28]]},"reference":[{"key":"9667_CR1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199810013391407","volume":"339","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN (1998) Treatment of breast cancer. N Eng J Med 339:974\u2013984","journal-title":"N Eng J Med"},{"key":"9667_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ctrv.1999.0161","volume":"26","author":"M Stockler","year":"2000","unstructured":"Stockler M, Wilcken NR, Ghersi D et al (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26:151\u2013168","journal-title":"Cancer Treat Rev"},{"key":"9667_CR3","first-page":"7","volume":"26","author":"JM Nabholtz","year":"1999","unstructured":"Nabholtz JM (1999) Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 26:7\u201313","journal-title":"Semin Oncol"},{"key":"9667_CR4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968\u2013975","journal-title":"J Clin Oncol"},{"key":"9667_CR5","first-page":"3257","volume":"24","author":"R Mattioli","year":"2004","unstructured":"Mattioli R, Lippe P, Massacesi C et al (2004) Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial. Anticancer Res 24:3257\u20133262","journal-title":"Anticancer Res"},{"key":"9667_CR6","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","volume":"17","author":"KD Miller","year":"1999","unstructured":"Miller KD, McCaskill-Stevens W, Sisk J et al (1999) Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033\u20133037","journal-title":"J Clin Oncol"},{"key":"9667_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000065466","volume":"63","author":"S Palmeri","year":"2002","unstructured":"Palmeri S, Leonardi V, Tamburo De et al (2002) Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Oncology 63:205\u2013212","journal-title":"Oncology"},{"key":"9667_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/B:BREA.0000036898.45123.e9","volume":"86","author":"A Morabito","year":"2004","unstructured":"Morabito A, Gattuso D, Stani SC et al (2004) Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat 86:249\u2013257","journal-title":"Breast Cancer Res Treat"},{"key":"9667_CR9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1078-0432.CCR-1000-03","volume":"10","author":"H To","year":"2004","unstructured":"To H, Shin M, Tabuchi M et al (2004) Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Clin Cancer Res 10:762\u2013769","journal-title":"Clin Cancer Res"},{"key":"9667_CR10","doi-asserted-by":"crossref","first-page":"8448","DOI":"10.1158\/0008-5472.CAN-05-1161","volume":"65","author":"M Tabuchi","year":"2005","unstructured":"Tabuchi M, To H, Sakaguchi H et al (2005) Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Cancer Res 65:8448\u20138454","journal-title":"Cancer Res"},{"key":"9667_CR11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1211\/002235703765951410","volume":"55","author":"H To","year":"2003","unstructured":"To H, Ohdo S, Shin M et al (2003) Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 55:803\u2013810","journal-title":"J Pharm Pharmacol"},{"key":"9667_CR12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff von","year":"1979","unstructured":"von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710\u2013717","journal-title":"Ann Intern Med"},{"key":"9667_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1388-9842(00)00111-2","volume":"2","author":"K Teraoka","year":"2000","unstructured":"Teraoka K, Hirano M, Yamaguchi K et al (2000) Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2:373\u2013378","journal-title":"Eur J Heart Fail"},{"key":"9667_CR14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1472-8206.2004.00282.x","volume":"18","author":"L Thomas","year":"2004","unstructured":"Thomas L, Bellmont S, Christen MO et al (2004) Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam Clin Pharmacol 18:649\u2013655","journal-title":"Fundam Clin Pharmacol"},{"key":"9667_CR15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/annonc\/mdg449","volume":"14","author":"G Ganem","year":"2003","unstructured":"Ganem G, Tubiana-Hulin M, Fumoleau P et al (2003) Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623\u20131628","journal-title":"Ann Oncol"},{"key":"9667_CR16","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","volume":"22","author":"E Alba","year":"2004","unstructured":"Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587\u20132593","journal-title":"J Clin Oncol"},{"key":"9667_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/15216540252774829","volume":"52","author":"A Mordente","year":"2001","unstructured":"Mordente A, Meucci E, Martorana GE et al (2001) Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83\u201388","journal-title":"IUBMB Life"},{"key":"9667_CR18","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","volume":"85","author":"RD Olson","year":"1988","unstructured":"Olson RD, Mushlin PS, Brenner DE et al (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585\u20133589","journal-title":"Proc Natl Acad Sci USA"},{"key":"9667_CR19","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1096\/fasebj.4.13.2210154","volume":"4","author":"RD Olson","year":"1990","unstructured":"Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076\u20133086","journal-title":"FASEB J"},{"key":"9667_CR20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1126\/science.877547","volume":"197","author":"CE Myers","year":"1977","unstructured":"Myers CE, McGuire WP, Liss RH et al (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165\u2013167","journal-title":"Science"},{"key":"9667_CR21","first-page":"909","volume":"260","author":"J Tong","year":"1991","unstructured":"Tong J, Ganguly PK, Singal PK (1991) Myocardial adrenergic changes at two stages of heart failure to adriamycin treatment in rats. Am J Physiol 260:909\u2013916","journal-title":"Am J Physiol"},{"key":"9667_CR22","first-page":"901","volume":"13","author":"NR Bachur","year":"1977","unstructured":"Bachur NR, Gordon SL, Gee MV (1977) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13:901\u2013910","journal-title":"Mol Pharmacol"},{"key":"9667_CR23","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/01.CIR.102.17.2105","volume":"102","author":"Li Timao","year":"2000","unstructured":"Timao Li, Singal PK (2000) Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102:2105\u20132110","journal-title":"Circulation"},{"key":"9667_CR24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF00685548","volume":"31","author":"MM al-Harbi","year":"1992","unstructured":"al-Harbi MM, al-Gharably NM, al-Shabanah OA et al (1992) Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol 31:200\u2013204","journal-title":"Cancer Chemother Pharmacol"},{"key":"9667_CR25","first-page":"430","volume":"269","author":"L Tesoriere","year":"1994","unstructured":"Tesoriere L, Ciaccio M, Valenza M et al (1994) Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther 269:430\u2013436","journal-title":"J Pharmacol Exp Ther"},{"key":"9667_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1014862912783","volume":"232","author":"T Li","year":"2002","unstructured":"Li T, Danelisen I, Singal PK (2002) Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem 232:19\u201326","journal-title":"Mol Cell Biochem"},{"key":"9667_CR27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.CIR.91.1.10","volume":"91","author":"N Siveski-Iliskovic","year":"1995","unstructured":"Siveski-Iliskovic N, Hill M, Chow DA et al (1995) Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 91:10\u201315","journal-title":"Circulation"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-007-9667-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9667-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:52Z","timestamp":1559233732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-007-9667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["9667"],"URL":"https:\/\/doi.org\/10.1007\/s10549-007-9667-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,28]]}}}